Veracyte, Inc.
Financials
Valuation Metrics
Veracyte, Inc.'s Market Cap is $3.91B. At end of 2025 it was $3.33B. Ranked #1508 of 3,118 in US market (top 48%), #523 of 1,474 on NASDAQ (top 35%), #98 of 203 in Health Care Equipment & Services (top 48%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.91B | US#1,508/3,118 Sec#98/203 |
| Revenue | $562M | US#2,190/3,118 Sec#140/203 |
| Net Income | $114M | US#1,561/3,118 Sec#79/203 |
| Total Assets | $1.49B | US#2,263/3,118 Sec#115/203 |
| Net Assets | $1.39B | US#1,520/3,118 Sec#79/203 |
| Employees | 755 | US#2,096/3,118 Sec#148/203 |
| Value | ||
| P/E | 34.15x | US#1,707/3,118 Sec#69/203 |
| P/B | 2.82x | US#1,722/3,118 Sec#87/203 |
| PEG | 0.10x | US#210/3,118 Sec#8/203 |
| P/S | 6.96x | US#2,549/3,118 Sec#168/203 |
| EV/EBITDA | 28.13x | US#2,187/3,118 Sec#113/203 |
| FCF Yield | 4.23% | US#1,556/3,118 Sec#79/203 |
| Profitability | ||
| ROE | 8.25% | US#1,556/3,118 Sec#77/203 |
| ROA | 7.70% | US#691/3,118 Sec#41/203 |
| Op. Margin | 17.03% | US#1,064/3,118 Sec#35/203 |
| Revenue Growth | 17.28% | US#797/3,118 Sec#52/203 |
| Earnings Growth | 334.72% | US#102/3,118 Sec#5/203 |
| Financial Health | ||
| Debt Ratio | 7.06% | US#64/3,118 Sec#4/203 |
| Total Debt | $40M | US#2,629/3,118 Sec#157/203 |
| FCF | $165M | US#1,480/3,118 Sec#86/203 |
| Cash | $300M | US#1,411/3,118 Sec#81/203 |
| Current Ratio | 9.16x | US#277/3,118 Sec#14/203 |
| Net Debt/EBITDA | -2.00x | US#172/3,118 Sec#13/203 |
| Performance | ||
| 1Y Return | 35.81% | US#622/3,118 Sec#60/203 |
| 1M Return | 6.96% | US#900/3,118 Sec#76/203 |
| From 52W High | -19.55% | US#1,359/3,118 Sec#116/203 |
| 1Y MDD | -39.23% | US#1,892/3,118 Sec#116/203 |
| Trading | ||
| Volume | 939,278 shares | US#1,708/3,118 Sec#120/203 |
| Trading Value | $47M | US#1,472/3,118 Sec#104/203 |
| Per Share | ||
| EPS | $1.43 | US#1,525/3,118 Sec#80/203 |
| BPS | $17.40 | US#1,383/3,118 Sec#78/203 |
Company Info
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.